Tesamorelin clinical trials give a fairly clear answer to one narrow question: in adults with HIV-associated lipodystrophy, a change in where the body stores fat, tesamorelin reduced visceral fat, the fat packed around the organs, more than placebo. They do not show that it causes broad weight loss or produces the same result in people without HIV.
That boundary is the part online summaries often lose. The best-known result came from two phase 3 studies, large late-stage trials, built around a CT scan rather than a scale or a before-and-after photograph.
Tesamorelin clinical trials: what did they ask?
The question was whether 26 weeks of tesamorelin could reduce visceral abdominal fat in adults with HIV who had developed excess abdominal fat while taking antiretroviral therapy. Placebo meant an inactive comparison injection.
Across the two studies, 816 people were randomized; the pooled analysis included 806 participants, split about two to one between tesamorelin and placebo. The two registry records are NCT00123253 and NCT00435136.
This was not a general obesity trial. Participants had HIV, were receiving antiretroviral treatment, and had measured abdominal enlargement. Their average age was 48, and 84% to 86% were men. That makes the results useful for the population studied and much less certain outside it.
What was measured, and how?
The primary endpoint, the main result chosen before the study began, was the percentage change in visceral adipose tissue after 26 weeks. A CT scan measured that deep abdominal fat directly. Subcutaneous fat, the softer layer under the skin, was measured separately.
The first trial enrolled 412 adults. In the 2007 New England Journal of Medicine paper, visceral fat fell 15.2% with tesamorelin and rose 5.0% with placebo. IGF-1, a blood marker downstream of growth-hormone signaling, rose 81% with tesamorelin and fell 5% with placebo.
The pooled result people quote
When both phase 3 studies were combined, the 26-week change in visceral fat was about −24 cm² with tesamorelin and +2 cm² with placebo. The reported between-group treatment effect was −15.4%. Abdominal subcutaneous fat did not change significantly.
IGF-1 rose by an average 108 ng/mL in the tesamorelin group and fell 7 ng/mL with placebo. That shows the hormone pathway responded. It does not turn a lab change into proof of longer life, better athletic performance, or a visible result for any one person.
The two trials also were not identical. The individual study results ranged from a 12% to a 20% advantage over placebo for visceral-fat change. Pooling gives a useful overall estimate, but it can hide that spread.
What the side-effect table showed
The current Egrifta WR label combines the same 26-week controlled safety set: 543 people received tesamorelin and 263 received placebo. These were the events reported more often with tesamorelin that matter most to the study story.
| Event | Tesamorelin | Placebo |
|---|---|---|
| Injection-site reaction | 17% | 6% |
| Joint pain | 13% | 11% |
| Muscle pain | 6% | 2% |
| Peripheral edema, or swelling in the limbs | 6% | 2% |
The label, revised March 2025, also reports that 5% of tesamorelin recipients versus 1% on placebo crossed the study threshold for diabetes. Averages can look reassuring while an individual still needs glucose and IGF-1 monitoring.
The trials did not test the ipamorelin blend
None of these studies combined tesamorelin with ipamorelin. The blend uses two different growth-hormone signals, so evidence for tesamorelin alone cannot establish the blend's effects, side effects, or dose. Tesamorelin and ipamorelin together explains that evidence gap without treating the two products as interchangeable.
What happened when treatment stopped?
After week 26, people who had received tesamorelin were assigned again: some stayed on it and others switched to placebo. That made the extension a useful test of whether the visceral-fat change lasted without continued treatment.
It did not. In the two studies, visceral fat rose 22% and 16% from week 26 to week 52 among groups switched to placebo. It changed 0% and −5% among those who continued. The extension paper described the fat as reaccumulating after discontinuation. This does not tell us exactly what happens to every patient, but it does rule out describing the 26-week change as permanent.
What later studies added
A small 2014 JAMA trial looked beyond visceral fat. Fifty adults with HIV and abdominal fat completed baseline assessment, and 48 received study drug. After six months, liver fat changed by −2.0 percentage points with tesamorelin and +0.9 with placebo, a net difference of −2.9 points (Stanley and colleagues). The authors called the liver result preliminary.
A 2019 Lancet HIV trial enrolled 61 adults with both HIV and fatty liver. At 12 months, the liver-fat difference was −4.1 percentage points versus placebo; 35% of the tesamorelin group and 4% of the placebo group ended below the study's 5% liver-fat threshold. Again, this was a specific HIV population, not evidence for ordinary fatty liver in the general public.
As of September 18, 2026, the day this article was written, the freshest pooled evidence is a systematic review published July 31, 2026. It combined four randomized trials with 909 participants and found 21.47 cm² less visceral fat versus placebo on average. It also found a higher, but statistically uncertain, rate of stopping for adverse events and called long-term safety and durability data limited.
How the gray market misreads the trials
The common leap is simple: a result in adults with HIV-associated fat redistribution becomes a promise about anyone's belly fat. Then a CT measurement becomes a weight-loss claim, and an IGF-1 rise becomes an anti-aging or muscle claim. The studies did not ask those questions.
They also did not test an anonymous vial, a custom blend, or a schedule copied from a forum. A result belongs first to the molecule, formulation, population, and protocol that produced it. Moving all four at once creates a new question, not the same answer.
What this means for a prescription today
Egrifta's regulatory history is covered in the guide to forms that are not FDA-approved, while tesamorelin cost handles brand, insurance, and compounded price paths. The clinical-trial takeaway is narrower: the strongest numbers belong to branded tesamorelin studied in adults with HIV-associated lipodystrophy.
Tesamorelin prescribed through Promise is dispensed by a licensed U.S. compounding pharmacy as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved. The brand trials cannot establish that a compounded preparation will match their results. A licensed provider may still prescribe a compounded formulation; that decision is between the patient and the doctor.
At Promise, a licensed provider reviews every request, and not everyone qualifies. The review weighs the treatment goal, cancer history, glucose, IGF-1, medicines, and the limits of the evidence above.
